Allakos Inc. (ALLK)
| Market Cap | 29.74M |
| Revenue (ttm) | n/a |
| Net Income | -70.85M |
| EPS | -0.79 |
| Shares Out | 90.38M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 725,841 |
| Open | 0.3283 |
| Previous Close | 0.3293 |
| Day's Range | 0.3283 - 0.3295 |
| 52-Week Range | 0.2200 - 1.5600 |
| Beta | 0.14 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 27, 2025 |
About ALLK
Allakos Inc., a clinical stage biotechnology company, engages in the development of therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company was incorporated in 2012 and is headquartered in San Carlos, California.
Financial Performance
Financial StatementsNews
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share
SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory ...
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results
SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammat...
Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to e...
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Allakos Inc. (NASDAQ: ALLK) breached their fi...
Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring
– AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host confe...
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and prolife...
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile –– ...
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and prolife...
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects treated with AK006 show high receptor occupancy...
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment ...
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and prolifer...
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and prolif...
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
– Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages –
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
– Data provide insights on the signaling pathways involved with AK006 mast cell inhibition –– AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells –
Allakos to stop further development of skin disease drug, plans job cuts
Allakos Inc said on Tuesday that it plans to discontinue the development of its experimental skin disease drug after it failed two mid-stage studies.
Allakos Announces a Restructuring to Focus on Development of AK006
SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and prolifera...
Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
SAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and prolife...
Allakos Appoints Neil Graham to its Board of Directors
SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on imm...
Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results
SAN CARLOS, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and prolife...
Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on imm...
Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition
– AK006 inhibits IgE mediated mast cell activation and shows similar IgE inhibitory activity as remibrutinib –– AK006 also inhibits non-IgE mast cell activation pathways, including KIT-mediated activa...